

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Termination of Security Interest in Patents
CONVEYING PARTY DATA	
Name	Execution Date
Bank of America, N.A., as Administrative Agent	09/28/2010
RECEIVING PARTY DATA	
Name:	Quest Diagnostics Incorporated
Street Address:	One Malcolm Avenue
City:	Teterboro
State/Country:	NEW JERSEY
Postal Code:	07608
PROPERTY NUMBERS Total: 45	
Property Type	Number
Patent Number:	5623415
Patent Number:	4963256
Patent Number:	5283334
Patent Number:	5284952
Patent Number:	5516636
Patent Number:	5281712
Patent Number:	5321136
Patent Number:	5395938
Patent Number:	4935339
Patent Number:	5705622
Patent Number:	5290936
Patent Number:	5284951
Patent Number:	5338847
Patent Number:	5656426
Patent Number:	4745181

OP \$1800.00 5623415

501306349

PATENT
REEL: 025066 FRAME: 0294

Patent Number:	4918192
Patent Number:	5110932
Patent Number:	5702887
Patent Number:	5395752
Patent Number:	5241070
Patent Number:	5663074
Patent Number:	5538901
Application Number:	08776849
Application Number:	09310106
Application Number:	08663150
Application Number:	08460444
Application Number:	08460459
Application Number:	60120175
Application Number:	09297710
Application Number:	08776981
Application Number:	08776850
Application Number:	09296075
Application Number:	09111898
Application Number:	09217792
Application Number:	09295853
Application Number:	09289354
Application Number:	09031087
Application Number:	08776851
Application Number:	09076512
Application Number:	08882414
Application Number:	09161555
Application Number:	09289158
Application Number:	09200223
Application Number:	09083650
Application Number:	09289157

CORRESPONDENCE DATA

Fax Number: (919)416-8328

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 9192868041

Email: pto_tmconfirmation@mvalaw.com

PATENT
REEL: 025066 FRAME: 0295

Correspondent Name:	Moore & Van Allen PLLC
Address Line 1:	430 Davis Drive
Address Line 2:	Suite 500
Address Line 4:	Morrisville, NORTH CAROLINA 27560

ATTORNEY DOCKET NUMBER:	017625-4570 JES
-------------------------	-----------------

NAME OF SUBMITTER:	John E. Slaughter
--------------------	-------------------

Total Attachments: 4 source=Termination - patents#page1.tif source=Termination - patents#page2.tif source=Termination - patents#page3.tif source=Termination - patents#page4.tif
--

TERMINATION OF SECURITY INTEREST IN PATENTS

This **TERMINATION OF SECURITY INTEREST IN PATENTS**, dated as of SEPTEMBER 28, 2010, is made by Bank of America, N.A., as Administrative Agent (the "Secured Party").

WHEREAS, Quest Diagnostics Incorporated (the "Grantor") has granted a security interest in certain personal property to the Secured Party, including without limitation a security interest in certain patents, patent applications, and/or patent licenses ("Patents");

WHEREAS, the security interest granted to the Secured Party was recorded at the United States Patent and Trademark Office on July 17, 2000 at Reel 010977 and Frame 0320; and

WHEREAS, the Secured Party has agreed to terminate and release its security interest in all of such Patents, including, without limitation, the Patents identified on Schedule III attached hereto.


NOW, THEREFORE, for valuable consideration, the Secured Party hereby terminates and releases all mortgages, liens, and security interests granted to the Secured Party in the following Patents:

1. all of the Grantor's Patents to which the Grantor is a party including those referred to on Schedule III attached hereto;
2. all reissues, continuations or extensions of the foregoing; and
3. all products and proceeds of the foregoing, including, without limitation, any claim by the Grantor against third parties for past, present or future infringement of any Patent.

IN WITNESS WHEREOF, the Secured Party has caused this Termination of Security Interest in Patents to be duly executed as of the date first set forth above.

Secured Party:

Bank of America, N.A., as Administrative Agent

By: 
Name: Zubin R. Shroff
Title: Vice President

SECURITY AGREEMENT
Schedule III – Initial Patents

Registered Owner	Patent Description	U.S. Patent Number ⁽ⁱ⁾
Quest Diagnostics Incorporated	Apparatus for Removing Closure from Container	08/776849 and 09/310106 ^{1, 2} Filed/Pending ^(s)
Quest Diagnostics Incorporated	Automated Apparatus for Subjecting Samples to Tests	08/663150; 08/460444; ^{3, 4} 08/460459; 5,623,415 ^{5, 6} 6Filed/Pending ^(s)
Quest Diagnostics Incorporated	Automated Specimen Processing System	60/120175 Filed/Pending ^(s) ⁷
Quest Diagnostics Incorporated	Universal Plug	09/297710 Filed/Pending ^(s) ⁸
Quest Diagnostics Incorporated	Mechanism for Releasably Locking Apparatus Together	08/776981 Filed/Pending ^(s) ⁹
Quest Diagnostics Incorporated	Holders for Vials Containing Biological Samples	08/776850 Filed/Pending ^(s) ¹⁰
Quest Diagnostics Incorporated	Collection Cup for On-Site Drug Testing System	09/296075 Filed/Pending ^(s) ¹¹
Quest Diagnostics Incorporated	Automated Centrifuge Loading Device	09/111,898; 09/217792 ^{12, 13} Filed/Pending ^(s)
Quest Diagnostics Incorporated	Automatic On-Site Drug Testing System	09/295853 Filed/Pending ^(s) ¹⁴
Quest Diagnostics Incorporated	Automation-Friendly Security Labels	09/289354 Filed/Pending ¹⁵
Quest Diagnostics Incorporated	Fluorescence Energy Transfer by Hybridization	09/031087 Filed/Pending ^(s) ¹⁶
Quest Diagnostics Incorporated	Free Hormones By Equilibrium Dialysis	4,963,256 ¹⁷
Quest Diagnostics Incorporated	Reagent and Method for Detecting an Adulterant in Sample	Filed/Pending ^(s)
Quest Diagnostics Incorporated and Universal Machine	Holding Device	08/776851 Filed/Pending ^(s) ¹⁸
Nichols Institute Diagnostics ⁽ⁱ⁾	Side Chain Substitution, Functional Acridinium Ester ^(d)	5,283,334 ¹⁹
Nichols Institute Diagnostics ⁽ⁱ⁾	Sulfonyl Chloride, Acridinium Ester Compounds ^(d)	5,284,952 ²⁰
Nichols Institute Diagnostics ⁽ⁱ⁾	Amplification Via Sensitizer Compounds ^(a)	5,516,636 ²¹
Nichols Institute Diagnostics ⁽ⁱ⁾	Ammonium Substituted, Acridinium Ester Compounds ^(d)	5,281,712 ²²
Nichols Institute Diagnostics ⁽ⁱ⁾	Peri-Substitution, Acridinium Ester Compounds ^(d)	5,321,136 ²³

- (a) Licensed non-exclusively to third parties
(b) Patent filed by third party exclusively licensed to NID, except where noted
(c) Copies of patent documentation are not currently available.
(d) Acridinium related patents non-exclusively licensed to Chiron Diagnostics
(e) Acridinium related patents non-exclusively licensed from Chiron Diagnostics

- (f) Co-ownership interest with third party
(g) Assigned to Quest Diagnostics in SBCL acquisition, including foreign counterpart applications
(h) SBCL's interest assigned to Quest in SBCL acquisition: co-owned with Capital Vial Inc.
(i) It is understood that foreign counterpart applications and patents, if any, are included.
(j) The assignee listed on the patents is London Diagnostics. However, all of London Diagnostics' assets, including the patents were acquired by NID.

Registered Owner	Patent Description	U.S. Patent Number ⁽ⁱ⁾	
Nichols Institute Diagnostics ^(j)	Biotin Acridinium Conjugates ^(d)	5,395,938	24
Nichols Institute Diagnostics ^(j)	Delayed Solid Phase ^(a)	4,935,339	25
Nichols Institute Diagnostics ^(j)	Sensitizer Conjugates Containing Porphyrins	5,705,622	26
Nichols Institute Diagnostics ^(j)	Nitro Substituted, Acridinium Ester Compounds ^(d)	5,290,936	27
Nichols Institute Diagnostics ^(j)	Hydrolytically Stable Acridinium Ester Compounds ^(d)	5,284,951	28
Nichols Institute Diagnostics ^(j)	Hydrolytically Stable Acridinium Ester Compounds ^(d)	5,338,847	29
Nichols Institute Diagnostics	Precision Improvement Using Dextran	09/076512 Filed/Pending	30
Nichols Institute Diagnostics	Acridinium Ester Tyramide Conjugated for Amplification	Draft ^(c)	
Nichols Institute Diagnostics	Dual Injector	08/882414 Filed/Pending	31
Nichols Institute Diagnostics	Anti-Foam for Liquid Level Sensing	09/161555 Filed/Pending	32
Nichols Institute Diagnostics	Device for Automated Fecal Specimen Handling	09/289158 Filed/Pending ^(c)	33
Nichols Institute Diagnostics	Digoxigenin-Thyroid Peroxidase Conjugate	09/200223 Filed/Pending	34
Nichols Institute Diagnostics	Magnetic Particle Resuspension Device	09/083650 Filed/Pending	35
Co-owned by NID and National Institutes of Health	Algorithm for Intra-Operative Tumor Removal	09/289,157 Filed/Pending ^(exn)	36
See footnote	Vitamin D Biotin Conjugates ^(b)	Filed ^(b) Notice of Allowance	
See footnote	Recombinant Thyroid Peroxidase	U.S. Patent Filed ^(b)	
See footnote	Recombinant Thyroid Receptor	U.S. Patent Filed ^{(b)(c)}	
See footnote	Disease Assoc. Human Auto Antibodies- Specific TPO	U.S. Patent Filed ^(b)	
See footnote	Functionalized Hydrophilic Acridium Esters ^(c)	5,656,426	37
See footnote	Polysubstituted Aryl Acridinium Esters ^(c)	4,745,181	38
See footnote	Polysubstituted Aryl Acridinium Esters ^(c)	4,918,192	39
See footnote	Polysubstituted Aryl Acridinium Esters ^(c)	5,110,932	40
See footnote	Long Emission Chemiluminescent Compounds ^(c)	5,702,887	41

- (a) Licensed non-exclusively to third parties
(b) Patent filed by third party exclusively licensed to NID, except where noted
(c) Copies of patent documentation are not currently available.
(d) Acridinium related patents non-exclusively licensed to Chiron Diagnostics
(e) Acridinium related patents non-exclusively licensed from Chiron Diagnostics

- (f) Co-ownership interest with third party
(g) Assigned to Quest Diagnostics in SBCL acquisition, including foreign counterpart applications
(h) SBCL's interest assigned to Quest in SBCL acquisition; co-owned with Capital Vial Inc.
(i) It is understood that foreign counterpart applications and patents, if any, are included.
(j) The assignee listed on the patents is London Diagnostics. However, all of London Diagnostics' assets, including the patents were acquired by NID.

Registered Owner	Patent Description	U.S. Patent Number ⁽ⁱ⁾	
See footnote	Long Emission Chemiluminescent Compounds ^(e)	5,395,752	42
See footnote	Nucleophilic Polysubstituted Acridinium Esters ^(e)	5,241,070	43
See footnote	Nucleophilic Polysubstituted Acridinium Esters ^(e)	5,663,074	44
See footnote	Nucleophilic Polysubstituted Acridinium Esters ^(e)	5,538,901	45

- (a) Licensed non-exclusively to third parties
- (b) Patent filed by third party exclusively licensed to NID, except where noted
- (c) Copies of patent documentation are not currently available.
- (d) Acridinium related patents non-exclusively licensed to Chiron Diagnostics
- (e) Acridinium related patents non-exclusively licensed from Chiron Diagnostics

- (f) Co-ownership interest with third party
- (g) Assigned to Qucst Diagnostics in SBCL acquisition, including foreign counterpart applications
- (h) SBCL's interest assigned to Quest in SBCL acquisition; co-owned with Capital Vial Inc.
- (i) It is understood that foreign counterpart applications and patents, if any, are included.
- (j) The assignee listed on the patents is London Diagnostics. However, all of London Diagnostics' assets, including the patents were acquired by NID.

Page 3 of 3